IL-22 treatment attenuates the inflammatory function of hepatocyte-derived mitochondrial DNA-enriched extracellular vesicles, thereby suppressing liver inflammation in NASH [82]. This evidence concerns the gene IL22 and metabolic dysfunction-associated steatohepatitis.